Biocon is in news today as its subsidiary, Biocon Biologics announced in the morning that it has received marketing authorisation from the UK’s MHRA for two biosimilars of Denosumab – Vevzuo and Evfraxy.

Denosumab is a monoclonal antibody used to treat osteoporosis and cancer-related bone diseases and is a multi-billion dollar global market.

Amgen’s original brands (Prolia/Xgeva) clocked over $4 billion in global sales annually.

Entering the UK and EU markets early gives Biocon a competitive edge as biosimilar adoption grows rapidly. It also sets the stage for entry into other regulated markets, including EMA (Europe) and possibly Health Canada and US FDA (if trials and filings are aligned).

Biocon already markets biosimilars like Trastuzumab (Herceptin), Bevacizumab (Avastin), and Insulins.

The company has seen muted performance in FY25 due to integration costs and margin pressures. Markets will see more upward traction in the stock only when commercial launch timelines are fixed.

The stock price has not reacted much though its making news with the price pricing little over 1% to Rs.381.80 with volumes also muted.